Web10 jun. 2024 · As for SCC, our previous study [ 8] revealed that PET response after CRT was predictive for distant metastasis-free survival (DMFS) and overall survival (OS) while Greally et al. [ 9] reported that PET response after induction chemotherapy was predictive for progression-free survival (PFS) and OS. WebAs compared with the standard regimen of cisplatin and fluorouracil, induction chemotherapy with the addition of docetaxel significantly improved progression-free and overall survival in patients...
DCF(導入化学療法) 2024.8 - 独立行政法人国立病院 ...
Web1 feb. 2024 · Induction DCF therapy may be ineffective for advanced-stage esophageal cancer and clinical lymph node metastasis and small decreases in SUVmaxDCF therapy are associated with early disease relapse and death. BACKGROUND/AIM The purpose of this study was to identify adverse prognostic factors for patients with advanced esophageal … WebInduction DCF chemotherapy and subsequent CS show acceptable toxicity and offer the chance of long-term survival in patients with locally advanced clinically unresectable … macrilen fda approval
Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction ...
Web7 nov. 2014 · In locally advanced or unresectable head-and-neck cancers, docetaxel, cisplatin and 5-FU (DCF) has been used as an induction chemotherapy, and showed a high response rate and improved survival [14, 15]. p53 is a well-known prognostic factor and predictive marker of a response to chemotherapy in head-and-neck squamous cell … Web31 mei 2024 · A total of 31 of the 239 patients (13.0%) had dose reductions of gemcitabine or cisplatin, mainly because of hematologic toxic effects (in 21 patients). Overall, the median relative dose intensity ... Web1 aug. 2024 · Induction chemotherapy has several aims for LAHNSCC. It can decrease the tumor volume in order to make a tumor resectable. Moreover, its goal is to eradicate … macril betametasona